TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00439075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Study: NCT03561948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
Study: NCT00143819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroskin Forte
Description: Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Application
Description: Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
Study: NCT02014181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: finely ground flaxseed powder
Description: 40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
Study: NCT01232673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMAC application in Critical Limb Ischemia
Description: Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
Study: NCT03415906

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sacubitril+valsartan
Description: Combined angiotensin receptor + neprilysin inhibition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Angiotensin receptor inhibition alone
Study: NCT00978900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial sweeteners; Carbohydrate Sugars
Description: sweetening agent dissolved in tap water, administered via intragastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT01835678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: orally 5 mg/d for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once a day for 4 weeks
Study: NCT01581957

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific Enteral Nutrition
Description: Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
Study: NCT05720572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antazoline
Description: Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Study: NCT02794909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary ultrasound exam
Description: The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
Study: NCT00986856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucidin® cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fucidin® cream
Study: NCT04336917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid Intercostal and Subserratus Plane Block with local anesthetic
Description: Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
Study: NCT02180100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terconazole Vaginal Suppository
Description: Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
Study: NCT00962442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: 300 mg/kg for 14 days, intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Glucosé 5% perfusion for 14 days, intravenously
Study: NCT02985099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Rosuvastatin gel
Description: SRP followed by 1.2% Rosuvastatin placement into intrabony defect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus placebo gel
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT03848689

Intervention type: OTHER
Intervention: fluoroquinolone preprescription authorization
Description: Requires authorization from Infection Control consult prior to prescribing fluoroquinolone

Intervention type: OTHER
Intervention: Control
Description: Does not require authorization from Infection Control prior to prescribing fluoroquinolone
Study: NCT03459118

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Function Focused Care
Description: The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function Focused Care
Description: The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
Study: NCT00625495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Intravenous infusion over 3 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Oral
Study: NCT01622192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florida Probe automated probe
Description: Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
Study: NCT03636620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation/microwave ablation
Description: radiofrequency ablation/microwave ablation
Study: NCT02841202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pills
Study: NCT02389751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04290338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIOMI
Description: Intraoral and extraoral stimulation.
Study: NCT00804570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2196044
Description: 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily, orally, 16 weeks
Study: NCT00487136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus ABT-335 plus rosuvastatin 5 mg
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus ABT-335 plus rosuvastatin 20 mg
Description: Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
Study: NCT00838292

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fortified blended flour - Insta Foundation Plus (with whey protein concentrate)
Description: 300 grams/day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fortified blended flour - Insta Foundation Plus (with whey protein concentrate)
Description: 300 grams/day for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling
Study: NCT00907751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
Study: NCT01129830

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: dehydroepiandrosterone
Description: DHEA supplementation 25 mg tid for 3 months
Study: NCT02042651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shockwave therapy
Description: Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low intensity extracorporeal shockwave therapy
Description: Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
Study: NCT01799187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: apexification
Description: apexification uses calcium hydroxide as root medication
Study: NCT01092143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: BI 671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate placebo
Description: Placebo matching Fluticasone propionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 671800 Placebo
Description: Placebo matching BI 671800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 671800 Placebo
Description: Placebo matching BI 671800
Study: NCT02801136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Study: NCT03978221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-extubation TDI
Description: A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
Study: NCT01529099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGMA HP PARTIAL KNEE
Description: SIGMA HP PARTIAL KNEE
Study: NCT02524548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
Study: NCT00749476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor IX recovery
Study: NCT01687140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Study: NCT04541979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aerosolized DNase
Description: DNase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0.9%, isotonic saline
Study: NCT04345770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX neoadjuvant or postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SOX neoadjuvant or postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
Study: NCT03505047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper Intrauterine device
Description: Immediate insertion of the copper intrauterine device after completion of abortion
Study: NCT01655420

Intervention type: PROCEDURE
Intervention: LASIK
Description: Laser eye surgery
Study: NCT04162184

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention
Description: a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
Study: NCT01230281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black bean seed coat extract
Description: 1000 mg oral daily dose for 2 weeks
Study: NCT00940381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
Study: NCT02431897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens Cream
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
Study: NCT03624933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Behavioral Coaching Session
Description: The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
Study: NCT03527082

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality.
Study: NCT01762215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PatientsLikeMe.com
Description: PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
Study: NCT03111485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Description: Capsule 250 mg / 50 mg taken at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Description: Capsule 250 mg / 50 mg taken at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Capsule taken at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Capsule taken at bedtime
Study: NCT01345747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal tube (VBM Medizintechnik, Sulz, Germany)
Description: laryngeal tube suction number 3 and 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal tube (VBM Medizintechnik, Sulz, Germany)
Description: laryngeal tube suction number 3 and 4
Study: NCT04533087

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention